Aplicações da metabolômica na predição de toxicidade à quimioterapia neoadjuvante para câncer de mama estádio iii

• Ano de defesa: 2015
• Autor(a) principal: Stella, Carolina Nigro [UNIFESP]
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: metabolomics; toxicity; chemotherapy; neoplasias breast; metabolômica; toxicidade; quimioterapia; neoplasias da mama
• Link de acesso: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=3194146; https://repositorio.unifesp.br/handle/11600/47282

Breast cancer is the most diagnosed cancer in women worldwide. Locally advanced breast cancer stage III represents the most advanced stage that is still potentially curable with surgery, radiation, and systemic therapy. Current neoadjuvant chemotherapy protocols allows better tumor resectability, either in the form of standard mastectomy or breast-conserving surgery. The antineoplastic drugs commonly used in these protocols have a large spectrum of side effects that must be predicted, detected and treated as soon as possible. Metabolomics is an emerging field for comprehensive profiling of metabolites in biofluids that can be used to find diagnostic biomarkers of many diseases, but its applications in assessment of treatment efficacy and side effects is still uncertain. The aim of this study was to define and quantify chemotherapy-induced side effects in women treated for advanced breast cancer (stage III) and evaluate the applications of plasma sample metabolomics in assessment of potential treatment toxicity. A total of 63 patients diagnosed with stage III breast cancer and treated with neoadjuvant chemotherapy ?AC-T? protocol, comprising 60mg/m2 Doxorubicin + 600mg/m2 Cyclophosphamide (4 cycles) and 175mg/m2 Paclitaxel (4 cycles) were selected. Metabolomic analysis performed in pre-chemotherapy plasma samples was compared to clinical and laboratory data collected during the treatment. Results lead to the conclusion that neoadjuvant chemotherapy can induce hematological toxicity and that FADS1 and ACADS activity can be potential biomarkers to predict chemotherapy-induced toxicity in patients, specially those with nuclear grade 1 and 2 tumors.